Breast Cancer      

Breast Cancer       image

Home » FOI request log » Breast Cancer      

FOI REFERENCE: 24422 FOI DATE:  10th October 2024       

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:   

  • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 0
  • Abemaciclib + Fulvestrant 23
  • Alpelisib + Fulvestrant 1
  • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide 0
  • Aromatase Inhibitor as a single agent 0
  • Atezolizumab 1
  • Capecitabine as a single agent 2
  • Carboplatin + Paclitaxel 3
  • Eribulin as a single agent or in combination 4
  • Everolimus + Exemestane 0
  • Fulvestrant as a single agent 39
  • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 0
  • Palbociclib + Fulvestrant 15
  • Parp Inhibitors (Olaparib/Talazoparib) 4
  • Pembrolizumab 16
  • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 0
  • Ribociclib + Fulvestrant 0
  • Sacituzumab Govitecan 6
  • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 0
  • Transtuzumab deruxtecan 0
  • Trastuzumab as a single agent or in combination 44
  • Trastuzumab emtansine 0
  • Any other active systemic anti-cancer therapy

KADCYLA (TRASTUZUMAB EMTANSINE) 11

PACLITAXEL 80 (WEEKLY) 23

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Add Aspirin – Breast cohort: 138

ATNEC: 1

Fast Forward: 87

Fast Forward Lymphatic sub study: 19

ICI-Genetics: 8

IMPORT-HIGH: 51

IMPORT-LOW: 62

INFORM: 109

MAMMO-50: 86

OPTIMA: 28

PARTNER: 47

POETIC-A: 7

POSNOC: 32

ROSCO: 9

SMALL: 8

Print this page
Email this page